Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Pressinotti, Nicole C ^a,b   Klocker, Helmut ^c   Schäfer, Georg ^d   Luu, Van Duc ^a,e   Ruschhaupt, Markus ^a   Kuner, Ruprecht ^a   Steiner, Eberhard ^c   Poustka, Annemarie ^a   Bartsch, Georg ^c   Sültmann, Holger ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^e Applied Biosystems   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; MESSENGER RNA; ONCOPROTEIN; PROTEIN PDIA3; UNCLASSIFIED DRUG; MAP3K5 PROTEIN, HUMAN; PDIA3 PROTEIN, HUMAN; PROTEIN DISULFIDE ISOMERASE; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL POPULATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; UBIQUITINATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MIDDLE AGED; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE KINASE 5; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; PROTEIN DISULFIDE-ISOMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 74549136665     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-130     Document Type: Article

References (37)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592. 10.1093/annonc/mdl498, 17287242.
2. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
3. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188. 2244693, 18283340, 10.1593/neo.07822.
4. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. 2007, 60:1238-1243.
5. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006, 7:355-362. 10.1007/s11864-006-0003-z, 16904052.
6. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006, 103:10991-10996. 1544162, 16829574, 10.1073/pnas.0603678103.
7. Lapointe J, Li C, Higgins JP, Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816. 321763, 14711987, 10.1073/pnas.0304146101.
8. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39:41-51. 10.1038/ng1935, 17173048.
9. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826. 10.1038/35090585, 11518967.
10. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 33173, 11309499, 10.1073/pnas.091062498.
11. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. 2004, 20:578-580.
12. Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004, 20:1464-1465. 10.1093/bioinformatics/bth088, 14962934.
13. Das S, Hahn Y, Nagata S, Willingham MC, Bera TK, Lee B, Pastan I. NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res 2007, 67:1594-1601. 10.1158/0008-5472.CAN-06-2673, 17308099.
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288. 10.1038/nrc776, 12001989.
15. Cooper CS, Campbell C, Jhavar S. Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. Nat Clin Pract Urol 2007, 4:677-687. 10.1038/ncpuro0946, 18059348.
16. Takeda K, Noguchi T, Naguro I, Ichijo H. Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol 2008, 48:199-225. 10.1146/annurev.pharmtox.48.113006.094606, 17883330.
17. Iriyama T, Takeda K, Nakamura H, Morimoto Y, Kuroiwa T, Mizukami J, Umeda T, Noguchi T, Naguro I, Nishitoh H, et al. ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis. Embo J 2009, 28:843-853. 10.1038/emboj.2009.32, 19214184.
18. Hail N, Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006, 11:1677-1694. 10.1007/s10495-006-9289-3, 16850162.
19. Joshi B, Li L, Taffe BG, Zhu Z, Wahl S, Tian H, Ben-Josef E, Taylor JD, Porter AT, Tang DG. Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res 1999, 59:4343-4355.
20. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994, 54:6167-6175.
21. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001, 61:5974-5978.
22. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275:90-94. 10.1126/science.275.5296.90, 8974401.
23. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagai S, Koyasu S, Matsumoto K, Takeda K, Ichijo H. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 2005, 6:587-592. 10.1038/ni1200, 15864310.
24. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006, 59:10-16. 1860255, 16394275, 10.1136/jcp.2005.027664.
25. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008, 68:1777-1785. 10.1158/0008-5472.CAN-07-5259, 18339858.
26. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007, 581:3641-3651. 2040386, 17481612, 10.1016/j.febslet.2007.04.045.
27. Corazzari M, Lovat PE, Armstrong JL, Fimia GM, Hill DS, Birch-Machin M, Redfern CP, Piacentini M. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer 2007, 96:1062-1071. 2360126, 17353921, 10.1038/sj.bjc.6603672.
28. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 2007, 141:41-50. 10.1016/j.surg.2006.05.009, 17188166.
29. Garbi N, Hammerling G, Tanaka S. Interaction of ERp57 and tapasin in the generation of MHC class I-peptide complexes. Curr Opin Immunol 2007, 19:99-105. 10.1016/j.coi.2006.11.013, 17150345.
30. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008, 15:1499-1509. 10.1038/cdd.2008.67, 18464797.
31. Garbi N, Tanaka S, Momburg F, Hammerling GJ. Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol 2006, 7:93-102. 10.1038/ni1288, 16311600.
32. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008, 101:809-816. 10.1111/j.1464-410X.2008.07502.x, 18321314.
33. Boer JM, Huber WK, Sultmann H, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Fuzesi L, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001, 11:1861-1870. 311168, 11691851.
34. Buness A, Huber W, Steiner K, Sultmann H, Poustka A. arrayMagic: two-colour cDNA microarray quality control and preprocessing. Bioinformatics 2005, 21:554-556. 10.1093/bioinformatics/bti052, 15454413.
35. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl 1):S96-104.
36. Bussey KJ, Kane D, Sunshine M, Narasimhan S, Nishizuka S, Reinhold WC, Zeeberg B, Ajay W, Weinstein JN. Matchminer: a tool for batch navigation among gene and gene product identities. Genome Biol 2003, 4:R27. 154578, 12702208, 10.1186/gb-2003-4-4-r27.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.